Replies to post #362733 on Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

Nasrat give Elite a discount? Not sure that’s likely given the original sale of Mikah drugs to Elite. Overvalued and Elite overpaid at the expense of a significant amount of dilution that hasn’t paid off to this day.

[IB_]

Uhhhh, I do not believe for one second that Nasrat will take a loss on his 50% of the Adderall product .....................................

With Elite as the buyer, he can get what he wants ... Who is going to hold him accountable for any move he makes ????????????????????????????

IB_

[snupoled]

WeeZuhl, stark Reality! My former diamond hands , cracked because of extreme temperatures tests by this company, fake diamond! Buyers remorse! Still glad I exited, loss is gonna hurt on next tax return! Snupdawgoled

[The ELTP King]

WRONG!


aELmTPa: "Can Elite's ART technology be applied to its CNS products?"

Nasrat: "That's a very good question and the answer is yes. Our technology works on all the products that affect the brain function especially the pleasure area even works on alcohol, okay. But this would require a rich partner. It's not an easy project. It cost a lot of money. How much money we spent on SequestOx and on development of the ART technology. We do have the technology. We can do it. We just need the resources. We raise the money internally or we find the partner who does that."

Our patented 2 bead antagonist ADF does not work with Adderall.

[WeeZuhl]

2-bead antagonist ADF does not work with Adderall

As I previously described, in detail, on 3/3/21:


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162286188

Let's be clear about what naltrexone can and cannot do. Naltrexone is a strong inhibitor of opioid receptors, especially mu receptors. It has a stronger affinity with the receptor than opioid molecules, so it blocks all available receptors and replaces any opioid that is already bound, which induces immediate opioid withdrawal. This is why it can be used in the 2 bead system as a "pharmacologic" ADF. Naltrexone is not a receptor inhibitor for any other classes of drugs, and so it *cannot* be used in a 2 bead ADF for any other class of drugs. But naltrexone does have other uses. I have had very good luck prescribing it for alcohol use disorder. An alcoholic user takes it every day, and they report significantly decreased cravings to drink alcohol. It is also approved as a maintenance drug for opioid use disorder, but it has never proven effective for this because opioid addicts tend to not take it. Naltrexone is also a part of a combination drug with bupropion ("Wellbutrin," "Xyban") for obesity called Contrave. It is unclear how those drugs work together, but the theory is they somehow regulate appetite through dopamine pleasure/reward pathways.

In the last SequestOx trial, the company also ran a new non-pharmacologic ADF oxycodone formulation. The new formulation was described as a "physical" ADF, meaning it is a hard-shell that resists crushing and cannot be hydrated for a syringe. These are PEG-based formulations that do not contain naltrexone. This kind of hard-shell ADF could be used to make an ADF version of Adderall or any other CNS stimulant.

Nasrat is correct to say Elite's *hard-shell* physical ADF technology can be used for CNS stimulants, but it would be incorrect to say the naltrexone 2 bead pharmacologic ADF can be used for CNS stimulants. When he refers to "pleasure area" and "even works on alcohol," I assume he is referring to naltrexone. The hard-shell ADF has no effect on the pleasure centers in the brain, and it certainly cannot be used for alcohol. IMO, Nasrat was just plain old confused in the last call. He was mixing up the hard-shell physical ADF, which can be used with Adderall, and naltrexone 2 bead pharmacologic ADF, which cannot be used with Adderall. The result was gibberish nonsense, which is now being replicated as gospel. Ignorance is bliss, so they say.